BridgeBio Pharma Inc’s recently made public that its Director Scott Randal W. unloaded Company’s shares for reported $85000.0 on Mar 01 ’24. In the deal valued at $34.00 per share,2,500 shares were sold. As a result of this transaction, Scott Randal W. now holds 6,500 shares worth roughly $0.17 million.
Then, Valantine Hannah sold 2,915 shares, generating $110,041 in total proceeds. Upon selling the shares at $37.75, the Director now owns 1,764 shares.
Before that, Valantine Hannah sold 2,915 shares. BridgeBio Pharma Inc shares valued at $110,683 were divested by the Director at a price of $37.97 per share. As a result of the transaction, Valantine Hannah now holds 1,764 shares, worth roughly $47328.119999999995.
A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in late January with a ‘”a Market perform”‘ rating. Wells Fargo began covering BBIO with “an Overweight” recommendation on December 08, 2023. Wells Fargo started covering the stock on December 08, 2023. It rated BBIO as “an Overweight”.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock fall -5.39% to $26.83. Over the last five days, the stock has lost -4.52%. BridgeBio Pharma Inc shares have fallen nearly -33.54% since the year began. Nevertheless, the stocks have risen 76.75% over the past one year. While a 52-week high of $44.32 was reached on 02/15/24, a 52-week low of $12.75 was recorded on 04/12/24. SMA at 50 days reached $31.37, while 200 days put it at $30.45. A total of 1.89 million shares were traded, compared to the trading of 1.6 million shares in the previous session.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 26.09, which if violated will result in even more drops to 25.35. On the upside, there is a resistance level at 27.85. A further resistance level may holdings at 28.87. The Relative Strength Index (RSI) on the 14-day chart is 36.71, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.38, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.53%. Stochastics %K at 19.67% indicates the stock is a buying.
The most recent change occurred on November 07, 2023 when Citigroup began covering the stock and recommended ‘”a Buy”‘ rating along with a $42 price target.
